The CRASH-19 trial is a multinational, open-label, factorial, randomised trial in adults hospitalised with suspected or confirmed acute COVID-19 infection.
We will evaluate the effect of aspirin (150mg once daily), losartan (100mg once daily), and
simvastatin (80mg once daily) in patients with COVID-19 infection.
Eligible patients will be randomly allocated to one of eight study arms (aspirin only;
losartan only; simvastatin only; aspirin and losartan; aspirin and simvastatin; losartan and
simvastatin; aspirin, losartan and simvastatin; standard care only). Trial treatments are
given in addition to the usual standard of care at the study hospital.
Treatment will be started as soon as possible after randomisation and will continue until
death, discharge or 28 days after randomisation, whichever occurs first.
Drug: Aspirin
Aspirin 150mg
Drug: Losartan
Losartan 100mg
Drug: Simvastatin
Simvastatin 80mg
Inclusion Criteria:
- Adults age 40 years and older
- with suspected or confirmed acute COVID-19 infection. Acute COVID-19 infection is
suspected in the presence of a fever and at least one symptom of respiratory disease
e.g. cough, difficulty breathing, signs of hypoxia. The clinician may suspect COVID-19
infection if i) the patient lives in or has recently travelled to an area with
COVID-19 transmission; ii) the patient had recent contact with a confirmed or probable
COVID-19 case, or iii) no alternative diagnosis fully explains the clinical
presentation
- requiring hospitalisation
Exclusion Criteria:
- Women known to be pregnant
- Patients hospitalised without symptoms of acute COVID-19 infection should not be
recruited even if they test positive for COVID-19
- Patients already receiving mechanical ventilation
- Patients with a definite indication or contraindication for any of the trial
treatments.
- Patients who are very severely frail (completely dependent and approaching end of life
who typically they could not recover even from a mild illness) or terminally ill
should not be recruited.
University College Hospital
Ibadan, Oyo, Nigeria
Shifa Tameer-e-Millat University
Rawalpindi, Pakistan